Design, synthesis and anticancer properties of IsoCombretaQuinolines as potent tubulin assembly inhibitors. 2017

Ilhem Khelifi, and Timothée Naret, and Dolor Renko, and Abdallah Hamze, and Guillaume Bernadat, and Jérome Bignon, and Christine Lenoir, and Joëlle Dubois, and Jean-Daniel Brion, and Olivier Provot, and Mouad Alami
BioCIS, Univ. Paris-Sud, CNRS, Université Paris-Saclay, 92290, Châtenay-Malabry, France.

The synthesis and evaluation of a new series of IsoCombretaQuinolines (IsoCoQuines) 2 with a 2-substituted-quinoline in place of the 3,4,5-trimethoxyphenyl ring present in isoCA-4 and CA-4 are described. Most of these compounds displayed a potent cytotoxic activity (IC50 < 10 nM) against a panel of five human cancer cell lines and inhibited tubulin assembly at a micromolar level. The most potent analogue 2b, having a 3-hydroxy-4-methoxyphenyl as B-ring, led to cell cycle arrest in G2/M phase. Docking studies indicate that 2b showed a binding mode comparable to those previously observed with quinazoline analogous (IsoCoQ) and with isoCA-4 at the colchicine binding site of tubulin.

UI MeSH Term Description Entries
D011799 Quinazolines A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring. Quinazoline
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D014404 Tubulin A microtubule subunit protein found in large quantities in mammalian brain. It has also been isolated from SPERM FLAGELLUM; CILIA; and other sources. Structurally, the protein is a dimer with a molecular weight of approximately 120,000 and a sedimentation coefficient of 5.8S. It binds to COLCHICINE; VINCRISTINE; and VINBLASTINE. alpha-Tubulin,beta-Tubulin,delta-Tubulin,epsilon-Tubulin,gamma-Tubulin,alpha Tubulin,beta Tubulin,delta Tubulin,epsilon Tubulin,gamma Tubulin
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D017209 Apoptosis A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. Apoptosis, Extrinsic Pathway,Apoptosis, Intrinsic Pathway,Caspase-Dependent Apoptosis,Classic Apoptosis,Classical Apoptosis,Programmed Cell Death,Programmed Cell Death, Type I,Apoptoses, Extrinsic Pathway,Apoptoses, Intrinsic Pathway,Apoptosis, Caspase-Dependent,Apoptosis, Classic,Apoptosis, Classical,Caspase Dependent Apoptosis,Cell Death, Programmed,Classic Apoptoses,Extrinsic Pathway Apoptoses,Extrinsic Pathway Apoptosis,Intrinsic Pathway Apoptoses,Intrinsic Pathway Apoptosis
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D049109 Cell Proliferation All of the processes involved in increasing CELL NUMBER including CELL DIVISION. Cell Growth in Number,Cellular Proliferation,Cell Multiplication,Cell Number Growth,Growth, Cell Number,Multiplication, Cell,Number Growth, Cell,Proliferation, Cell,Proliferation, Cellular
D050257 Tubulin Modulators Agents that interact with TUBULIN to inhibit or promote polymerization of MICROTUBULES. Microtubule Modulator,Tubulin Inhibitor,Tubulin Modulator,Tubulin Polymerization Inhibitor,Tubulin Polymerization Promoter,Tubulin Promoter,Microtubule Modulators,Tubulin Inhibitors,Tubulin Polymerization Inhibitors,Tubulin Polymerization Promoters,Tubulin Promoters,Inhibitor, Tubulin,Inhibitor, Tubulin Polymerization,Inhibitors, Tubulin,Inhibitors, Tubulin Polymerization,Modulator, Microtubule,Modulator, Tubulin,Modulators, Microtubule,Modulators, Tubulin,Polymerization Inhibitor, Tubulin,Polymerization Inhibitors, Tubulin,Polymerization Promoter, Tubulin,Polymerization Promoters, Tubulin,Promoter, Tubulin,Promoter, Tubulin Polymerization,Promoters, Tubulin,Promoters, Tubulin Polymerization

Related Publications

Ilhem Khelifi, and Timothée Naret, and Dolor Renko, and Abdallah Hamze, and Guillaume Bernadat, and Jérome Bignon, and Christine Lenoir, and Joëlle Dubois, and Jean-Daniel Brion, and Olivier Provot, and Mouad Alami
July 2020, European journal of medicinal chemistry,
Ilhem Khelifi, and Timothée Naret, and Dolor Renko, and Abdallah Hamze, and Guillaume Bernadat, and Jérome Bignon, and Christine Lenoir, and Joëlle Dubois, and Jean-Daniel Brion, and Olivier Provot, and Mouad Alami
December 2022, Bioorganic & medicinal chemistry,
Ilhem Khelifi, and Timothée Naret, and Dolor Renko, and Abdallah Hamze, and Guillaume Bernadat, and Jérome Bignon, and Christine Lenoir, and Joëlle Dubois, and Jean-Daniel Brion, and Olivier Provot, and Mouad Alami
May 2017, MedChemComm,
Ilhem Khelifi, and Timothée Naret, and Dolor Renko, and Abdallah Hamze, and Guillaume Bernadat, and Jérome Bignon, and Christine Lenoir, and Joëlle Dubois, and Jean-Daniel Brion, and Olivier Provot, and Mouad Alami
October 2020, Bioorganic & medicinal chemistry,
Ilhem Khelifi, and Timothée Naret, and Dolor Renko, and Abdallah Hamze, and Guillaume Bernadat, and Jérome Bignon, and Christine Lenoir, and Joëlle Dubois, and Jean-Daniel Brion, and Olivier Provot, and Mouad Alami
February 2022, European journal of medicinal chemistry,
Ilhem Khelifi, and Timothée Naret, and Dolor Renko, and Abdallah Hamze, and Guillaume Bernadat, and Jérome Bignon, and Christine Lenoir, and Joëlle Dubois, and Jean-Daniel Brion, and Olivier Provot, and Mouad Alami
August 2022, Pharmaceuticals (Basel, Switzerland),
Ilhem Khelifi, and Timothée Naret, and Dolor Renko, and Abdallah Hamze, and Guillaume Bernadat, and Jérome Bignon, and Christine Lenoir, and Joëlle Dubois, and Jean-Daniel Brion, and Olivier Provot, and Mouad Alami
November 2020, Bioorganic chemistry,
Ilhem Khelifi, and Timothée Naret, and Dolor Renko, and Abdallah Hamze, and Guillaume Bernadat, and Jérome Bignon, and Christine Lenoir, and Joëlle Dubois, and Jean-Daniel Brion, and Olivier Provot, and Mouad Alami
September 2014, Journal of medicinal chemistry,
Ilhem Khelifi, and Timothée Naret, and Dolor Renko, and Abdallah Hamze, and Guillaume Bernadat, and Jérome Bignon, and Christine Lenoir, and Joëlle Dubois, and Jean-Daniel Brion, and Olivier Provot, and Mouad Alami
September 2020, European journal of medicinal chemistry,
Ilhem Khelifi, and Timothée Naret, and Dolor Renko, and Abdallah Hamze, and Guillaume Bernadat, and Jérome Bignon, and Christine Lenoir, and Joëlle Dubois, and Jean-Daniel Brion, and Olivier Provot, and Mouad Alami
October 2010, Journal of medicinal chemistry,
Copied contents to your clipboard!